Stem Cell Therapy Indications and Contraindications
Make sure the exact cell product, your diagnosis and your current health actually line up before you spend on travel or commit to a procedure.
We organize your records, hold the proposed option up against current evidence and Japan’s regulatory pathway, flag questions that could affect eligibility, and prepare a clean case summary ready for a licensed doctor’s review.
Information, translation and coordination support only. Licensed medical professionals handle all diagnosis, prescribing and treatment decisions.
The label “stem cell therapy” is not specific enough
Four very different pathways can sit behind the same phrase. Your evidence, risks, cost and eligibility depend on which one is actually being proposed.
Hematopoietic stem-cell transplantation
Used for selected blood cancers and serious blood disorders. Candidacy depends on the diagnosis, disease status, transplant type, donor factors, organ function and overall fitness.
A named regenerative medical product with a defined indication
Approval applies to the named product, patient group, route and indication. It does not make other MSC, iPS or cell products equivalent.
Regenerative medicine provided under the safety law
A notified provision plan follows Japan’s regenerative medicine safety framework. That is different from PMDA marketing approval for a regenerative medical product.
A clinical study or investigational cell intervention
Early human data may be useful, but the result can change with cell source, dose, route, timing, disease stage and trial design.
“Approved in Japan” must be checked product by product
PMDA’s current list shows why broad statements don’t hold up. The approved indication is narrow and tied to a specific product.
Allogeneic bone marrow-derived MSCs
Approved in 2015 for acute graft-versus-host disease following hematopoietic stem-cell transplantation. This does not mean MSC infusion is approved for unrelated conditions.
Allogeneic iPS-derived dopaminergic progenitor cells
PMDA lists approval in March 2026. The indication is motor symptoms in Parkinson’s disease with inadequate response to conventional drug therapy including levodopa. Approval is conditional and time-limited.
Allogeneic iPS-derived cardiomyocyte sheets
PMDA lists approval in March 2026 for severe heart failure due to ischemic cardiomyopathy after inadequate response to standard care. The product uses surgical placement and post-procedure immunosuppression. Approval is conditional and time-limited.
Japan’s Act on the Safety of Regenerative Medicine was amended effective May 31, 2025. Check the exact legal pathway and the exact product before comparing claims.
Approval does not by itself confirm that a specific person is eligible, that access is available, or what an individual will pay.
Read the Japan registration and compliance guideWhere common patient questions stand today
Use the exact diagnosis and stage. A positive study in one condition doesn’t support a broad claim for another.
Blood cancers and marrow disorders
Established in selected casesHematopoietic stem-cell transplantation has established roles in selected leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes and some serious non-malignant blood disorders. Survival and relapse risk depend on the exact disease and transplant setting, so there is no single “stem cell survival rate.”
Parkinson’s disease
Product-specific approvalJapan now has a conditional, time-limited iPS-derived product for a narrow Parkinson’s population with inadequate response to conventional drug therapy. This is a stereotactic cell-replacement procedure, not a generic intravenous MSC infusion.
Knee osteoarthritis
InvestigationalHuman trials have reported changes in pain and function in selected patients, but results differ by cell preparation and study design. Cartilage regrowth and avoidance of joint replacement should not be guaranteed.
See knee evidence and patient factorsSpinal cord injury
Therapy and timing specificClinical experience includes several cell types, but injury level, completeness and time from injury strongly affect interpretation. Evidence from an acute or incomplete injury should not be applied to chronic complete injury.
See spinal cord injury evidence
Ischemic stroke
InvestigationalThe 206-participant TREASURE randomized trial did not show a significant improvement in its 90-day primary efficacy endpoint with intravenous MultiStem versus placebo. Cell therapy remains investigational and does not replace acute stroke care, prevention or rehabilitation.
See stroke and cerebrovascular evidenceType 1 diabetes
Promising trial dataStem-cell-derived islet replacement has produced insulin independence in a small early study, but it is not the same as generic MSC therapy and the studied approach requires immunosuppression. Longer and larger studies are still important.
See diabetes evidence and limitsType 2 diabetes
No generic cell standardCell-based proposals should be compared with established glucose, cardiovascular and weight-management care. Prescribed insulin or other medication should not be stopped because of a cell-therapy claim.
See diabetes evidence and limitsSevere ischemic heart failure
Product-specific approvalRiHEART has a narrow conditional, time-limited indication in Japan after inadequate response to standard care. It involves cardiomyocyte sheets, surgical placement and a defined immunosuppression regimen, not a general cell infusion.
See cardiovascular evidence
Liver or kidney dysfunction
InvestigationalCell therapy is not an established replacement for dialysis, transplant evaluation or disease-specific standard care. Cause, stage and remaining organ function should be defined first.
See liver and kidney evidenceChronic pain
Cause dependentChronic pain is a symptom, not one cell-therapy indication. Joint degeneration, tendon injury, neuropathy, spine disease and inflammatory causes need different evidence and different outcome measures.
See chronic pain evidenceOvarian function and fertility
Limited early evidenceHormone markers, ovarian reserve and pregnancy outcomes are separate endpoints. Cell-based approaches should not be presented as a guaranteed restoration of fertility.
See ovarian regeneration evidenceErectile dysfunction and anti-aging claims
Limited or insufficient evidenceED needs vascular, neurologic, endocrine and medication causes separated. Broad anti-aging or rejuvenation claims should be judged by specific measurable endpoints, not general promises.
See ED evidence See anti-aging evidenceNot sure which evidence applies to what you were offered?
Send the exact product name, cell source, route and your latest diagnosis summary. We will help separate what matches from what does not.
Numbers matter only when the study matches your situation
The examples below show why the product, population and endpoint can’t be separated from the number.
Type 1 diabetes: insulin independence at day 365
In the 2025 phase 1-2 zimislecel report, 10 of 12 full-dose participants were insulin-independent at one year. The study was small and short-term, used allogeneic stem-cell-derived islets and required immunosuppression.
New England Journal of Medicine, 2025Ischemic stroke: randomized participants in TREASURE
At day 90, the primary “excellent outcome” endpoint was 11.5% with MultiStem and 9.8% with placebo, with no significant difference. The trial does not support a broad claim that intravenous cell therapy restores stroke function.
JAMA Neurology, 2024AMCHEPRY: conditional and time-limited approval period
PMDA’s review specifies a seven-year conditional approval period and continued post-marketing evaluation because available information is limited.
PMDA review report, 2026RiHEART: product-specific administration
PMDA’s review specifies three cardiomyocyte sheets placed on the heart surface, in principle through left thoracotomy, followed by three immunosuppressants for 90 days. This is not comparable with a simple outpatient cell infusion.
PMDA review report, 2026Ask for the endpoint that actually fits your condition
There isn’t one “success rate” or “survival rate” that works across all cell therapies. The endpoint has to match the disease.
For blood cancers or severe heart failure, survival and major events can matter. For knee osteoarthritis, Parkinson’s disease or chronic pain, function and symptom measures are usually more useful.
Pain score, WOMAC or KOOS, walking and function, need for later surgery.
AIS neurological grade, motor or sensory change, SCIM and daily function.
Modified Rankin Scale, NIHSS, Barthel Index and independence over defined follow-up.
MDS-UPDRS motor scores, OFF-state function, medication needs and adverse effects.
C-peptide, severe hypoglycemia, HbA1c, time in range and insulin independence.
Survival, hospitalization, exercise tolerance, symptoms and cardiac function.
Overall survival, relapse-free survival, treatment-related mortality and graft complications.
Use validated hormone, fertility or function endpoints instead of broad “rejuvenation” claims.
Reasons a plan may need to be delayed, changed or declined
These are common screening issues, not universal exclusions. The exact contraindications come from the specific product, route, procedure and protocol.
Infection can raise procedural and immune-related risk and may need to be controlled before elective cell-based care.
An unstable condition may require standard urgent or specialist care before an elective regenerative option can be considered.
Harvest, injection or surgery can change bleeding risk. Prescribed anticoagulants should only be adjusted by the responsible medical professional.
Kidney, liver, cardiac or pulmonary impairment can affect anesthesia, surgery, drug clearance or ability to tolerate immunosuppression.
Oncology-directed stem-cell transplantation is a different situation. A non-oncology regenerative proposal needs cancer history reviewed separately.
Some allogeneic or iPS-derived products require immune suppression and structured follow-up. If those parts cannot be completed safely, the whole plan may not fit.
Pregnancy, reproductive plans, severe allergies, frailty, recent surgery and other factors can also be protocol-specific screening issues.
“Autologous” or “minimally invasive” does not mean risk-free
Risk shifts with where the cells come from, how they’re processed, where they land, and whether surgery or immunosuppression is part of the deal.
Read the Japan safety guideInfusion reactions, infection and route-specific vascular risks must be considered. An IV route also does not prove that enough viable cells reach the intended tissue.
Bleeding, infection, pain and injury to nearby structures depend on the target site and imaging or procedural technique.
Anesthesia, access surgery, bleeding, infection and recovery burden can be larger than the cell product itself suggests.
Immune response, immunosuppression and long-term monitoring can be central parts of the risk profile. Pluripotent-cell-derived products also require careful control for unwanted cell growth.
Using your own cells avoids some donor-related issues but does not remove harvest, contamination, processing or administration risks.
A procedure can be technically successful and still fail to improve the outcome that matters to you. Ask what percentage improved on the same validated endpoint and at what time point.
There is no honest single price for “stem cell therapy in Japan”
A self-pay infusion, a surgical iPS-derived product and a hematopoietic transplant aren’t even in the same ballpark. Before you travel, ask for one itemized total.
A national reimbursement price for an approved product is not automatically the amount an international self-pay patient will pay.
Recovery should be measured, not described as “feeling better”
The plan should spell out the baseline, the observation window and what will actually be measured after the procedure.
Record a baseline
Current symptoms, validated function scores, imaging or laboratory markers, medication and rehabilitation level should be documented before comparing change.
Separate procedure recovery from biological effect
Pain, fatigue or short-term change after an injection or surgery should not automatically be counted as evidence that cells are working.
Use planned checkpoints
Many research protocols use defined checkpoints such as 1, 3, 6 or 12 months, but the correct schedule depends on the product and condition. Compare the same validated outcome each time.
Know who follows safety and what happens if there is no benefit
Ask how delayed adverse events are tracked, whether repeat treatment is evidence-based, and what standard care or rehabilitation continues if the target outcome is not reached.
New major weakness, severe breathlessness, chest pain, heavy bleeding, high fever or rapid deterioration should not wait for routine messaging support.
A clearer case before you make a major decision
We organize medical information, translate documents and coordinate in Japan. We don’t diagnose, prescribe, sell cell products or guarantee eligibility.
A structured case summary, missing-record list, evidence and regulatory questions, cost-scope checklist, and a concise set of questions for a licensed medical professional.
Organize your records
Diagnosis, timeline, imaging reports, key laboratory results, medication, prior procedures and current functional status are put into one readable summary.
Match the exact proposal
We separate cell source, product name, route, dose and claimed indication, then compare those details with the evidence and Japan regulatory pathway.
Build the questions that matter
Eligibility, contraindications, alternatives, realistic endpoints, serious risks, cell quality, cost scope and follow-up are turned into a concise question list.
Support communication in Japan
We help with document translation, information transfer and coordination so the licensed medical professional reviewing the case receives a clearer set of records and questions.
Useful checks before you decide
Open only the topic that answers the next question in your decision, rather than reading the same general explanation again.
Six details should be written down, not left as verbal promises
Cell identity and source: exact product or cell type, autologous or allogeneic, and tissue source.
Dose and route: number of cells or units, number of administrations, and how the cells reach the target.
Quality release checks: identity, viability, sterility and other release criteria relevant to the specific product.
Japan legal pathway: named PMDA-approved product, provision under the regenerative medicine safety framework, or clinical research.
Expected endpoint: the same validated outcome and follow-up period used in the evidence being cited to you.
Total scope: full cost, exclusions, aftercare, adverse-event plan, cancellation terms and repeat-treatment policy.
Ask whether the exact cell preparation being offered matches the exact evidence being quoted.
Short answers before you move forward
These are the points most likely to change eligibility, expected benefit or cost.
Can my diagnosis alone tell me whether I qualify?
No. Disease stage, current stability, prior treatment, infection, cancer history, organ function, medication, imaging, functional status, cell type and route can all change eligibility.
Does “MSC therapy” tell me enough to judge the evidence?
No. Ask for the tissue source, autologous or allogeneic status, manufacturing process, dose, route and exact indication. Evidence for one MSC product cannot automatically be applied to another.
Is older age automatically a contraindication?
Not automatically. Age may affect risk, but fitness, frailty, heart and lung status, kidney and liver function, medication, the proposed procedure and protocol-specific age limits can matter more than age alone.
Should I stop insulin, anticoagulants or other prescribed medicine?
Do not stop prescribed medication because of general online advice or a sales claim. Any change should be made by the licensed medical professional responsible for that medication and coordinated with the professional reviewing the proposed procedure.
Does a Japan regenerative medicine plan mean the product is PMDA approved?
No. Japan’s regenerative medicine safety framework and PMDA marketing approval are separate pathways. Ask which pathway applies to the exact cell product or procedure being offered.
How do I know whether the quoted success rate applies to me?
Match the study population, diagnosis and stage, cell source, dose, route, comparison group, endpoint and follow-up time. If several of these differ from your proposal, the percentage is not directly transferable.
What records should I send first?
Start with the diagnosis, latest medical summary, relevant imaging reports, recent laboratory results, current medication list, prior procedures, allergies and major infection, cancer, bleeding, heart, lung, liver or kidney history. Only share information you are comfortable sending through your chosen channel.
Current sources used for verification
Regulatory status and clinical evidence can change. Check the exact product and indication again before making a decision.
Get the important questions clear before you commit
Send your diagnosis, latest medical summary, current medication list and key imaging or lab reports. We’ll organize the information, flag what’s missing, and line up the evidence, eligibility, risk, cost and follow-up questions that need a licensed medical review.
We support information organization, document translation and coordination. We don’t offer diagnosis, prescriptions, medical treatment or treatment guarantees.